Else Nutrition H Stock Price, News & Analysis

Else Nutrition Holdings (BABYF) has scheduled a business update conference call for September 16, 2025, at 10:00 a.m. Eastern Time. The call will discuss the company's Q2 2025 financial results and corporate developments.

Investors can access the call via telephone (toll-free 1-877-407-9219 for U.S. callers or +1-412-652-1274 for international callers) or through a webcast. A replay will be available on the company's investor relations website through September 16, 2026, and via telephone through September 30, 2025.

Else Nutrition (OTCQX: BABYF) reported its Q1 2025 financial results, maintaining revenue at $2.1 million year-over-year while significantly improving operational efficiency. The company achieved a notable reduction in operating expenses by 48% to $2.2 million and increased gross profit margin to 25% from 8% in Q1 2024.

Key strategic initiatives include shifting powder formula manufacturing to Europe to reduce production costs and improve margins. The company is also optimizing its retail distribution model and pursuing regulatory advancement through Operation Stork Speed and the FY2026 Agriculture Appropriations Bill, which could streamline FDA approval pathways for plant-based infant nutrition alternatives.

The company ended Q1 2025 with a cash balance of $0.2 million, including restricted cash, and is exploring strategic collaborations to accelerate growth.

Else Nutrition (OTCQX: BABYF) has scheduled a business update conference call for Thursday, August 21, 2025, at 10:00 a.m. Eastern Time. The call will discuss the company's Q1 2025 financial results and corporate developments.

Investors can access the call via telephone (toll-free: 1-877-407-9219 for U.S. callers; +1-412-652-1274 for international) or webcast. A replay will be available through August 21, 2026, on the company's investor relations website, with telephone replay accessible until September 3, 2025.

Else Nutrition Holdings (OTCQX:BABYF) has received approval from the Toronto Stock Exchange for an additional extension to hold its 2025 Annual General Meeting (AGM). The company, which previously announced a delay on June 19, 2025, is now required to conduct the AGM by September 30, 2025.

Else Nutrition (OTCQX: BABYF) welcomes a significant legislative development as the U.S. House Appropriations Committee passes the FY2026 Agriculture and FDA Appropriations Bill. The legislation specifically directs the FDA to streamline approval pathways for plant-based, non-soy, and non-dairy infant formulas.

The bill includes crucial language supporting alternative infant formula access and calls for formal regulatory guidance for non-dairy, non-soy plant-based formulas. This initiative is part of Operation Stork Speed, the Administration's effort to accelerate innovation in infant formula. While the legislation still needs full House approval, it represents a significant step toward expanding the U.S. infant formula market and potentially expediting Else Nutrition's market access.

Else Nutrition Holdings (BABYF) has received a cease trade order (CTO) from the British Columbia Securities Commission due to delayed filing of its Q1 2025 financial statements and related documents. The CTO prohibits trading of company securities in Canada until the interim filings are completed and the order is revoked. Limited exceptions exist for non-insider beneficial shareholders who acquired securities before June 16, 2025, allowing sales through foreign regulated markets via registered Canadian investment dealers. The company expects to file the required documents by June 30, 2025. Additionally, the Toronto Stock Exchange has granted an extension for the company's annual general meeting from June 30 to July 31, 2025.

Else Nutrition (BABYF) welcomes three major U.S. federal developments that could revolutionize the infant formula market, particularly for plant-based alternatives. The FDA-commissioned National Academy of Sciences study recommends replacing the outdated Protein Efficiency Ratio test with modern standards, aligning with Else's regulatory approach. Congressional Republican Appropriators have urged the FDA to create a modernized pathway for plant-based infant formula, while the Administration launched 'Operation Stork Speed' to streamline regulatory processes. These developments could pave the way for Else Nutrition to commercialize the world's first whole-food, dairy-free infant formula. The company is mobilizing stakeholders through a grassroots campaign to advocate for inclusive, evidence-based nutrition standards.

Else Nutrition (BABYF) reported its fiscal year 2024 results, showing a 14.8% revenue decline to $8 million from $9.4 million in 2023. The company faced significant challenges including funding constraints, inventory shortages, and limited marketing budget. Operating expenses decreased 20% to $13.6 million from $16.9 million in 2023, with cash balance at $0.3 million as of December 31, 2024. Management implemented strategic changes including cost reduction, operational optimization, and closure of Israel lab. Notable achievements include launching Adult Ready-to-Drink product and expanding Kids RTD retail presence. The company is engaged with FDA's Operation Stork Speed initiative to modernize guidelines for plant-based infant formula. Future plans include expanding retail distribution, scaling European production, and enhancing brand visibility.

Else Nutrition (BABYF) CEO Hamutal Yitzhak published an op-ed in The Washington Times discussing Operation Stork Speed, an initiative aimed at modernizing infant formula regulations and increasing access to innovative nutrition options. The company has developed a plant-based infant formula as an alternative to dairy and soy-based products, targeting families with dietary restrictions and allergen sensitivities.

The company has completed pre-clinical studies and received IRB approval for its infant growth clinical study protocol. Else Nutrition is currently awaiting FDA authorization to begin clinical trials in the United States, which may be expedited through Operation Stork Speed. The initiative, launched by the Trump administration and HHS Secretary Robert F. Kennedy Jr., focuses on improving regulatory review and safety of infant formula while encouraging innovation.